Lymphocyte T-Cell Immunomodulator has received a conditional license from the United States Department of Agriculture. Additional efficacy and potency studies are in progress. LTCI is manufactured and distributed by T-Cyte Therapeutics, Inc.
LTCI is an approved treatment aid for cats infected with Feline Leukemia Virus (FeLV) and/or Feline Immunodeficiency Virus (FIV) and the associated symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia, and thrombocytopenia.
LTCI Immunopharmacology
Lymphocyte T-Cell Immune Modulator is a potent regulator of CD-4 lymphocyte production and function and increases IL-2 production.
IL-2 Production
LTCI increases the production of IL-2. IL-2 is known to stimulate cytotoxic T-cell responses against viruses.
IL2-Production
|
|
LTCI has been shown to increase IL-2 production in the Jurkat cell line (Fig. 1). Jurkat cells are a standard cell line used to study T-cell signaling and leukemia.
Hematopoietic Properties
It is now accepted that T-cells participate in the production of red and white blood cells and platelets. LTCI, a T-cell immune modulator, has been shown to increase RBC counts in severely anemic cats and increase lymphocyte counts.
Additionally, LTCI treatment was shown to significantly increase platelet recovery in a chemotherapy induced thrombocytopenia model in mice (Fig. 2).
Treatment Effects of LTCI After Three Injections
|
Clinic Score After Three LTCI Injections
|
LTCI Safety First
Clients depend on safe products for their pets. Veterinarians demand safe products for treating ill patients. LTCI has completed formal safety testing. The homology of LTCI among mammalian species, as well as, the absence of any observed adverse events in several animal species, suggests that LTCI has a very low toxicity profile.
LTCI EFFICACY DATA
FeLV and FIV Field Trial
LTCI has been evaluated in FeLV and FIV symptomatic cats. In a 23 cat study, three weekly injections of LTCI significantly increased lymphocyte counts and increased the quality of life as determined by clinical scores
LTCI Effect on Platelet Recovery
|
LTCI Has Been Shown to:
The long-term benefits of treatment have not been clinically established. However, several animals in the field trial that received monthly or bimonthly injections have remained symptom free for long periods. Two patients in the trial also became negative for virus by PCR analysis of bone marrow aspirates.
Lymphocyte T-Cell Immunomodulator has received a conditional license from the United States Department of Agriculture. Additional efficacy and potency studies are in progress. LTCI is manufactured by T-Cyte Therapeutics, and is distributed by T-Cyte Therapeutics.
LTCI Use and Monitoring
Clinical Signs:
The most important monitoring method is clinical improvement. Each patient should be monitored for clinical signs associated with their infection(s) and a scoring system may be established to monitor patient progress..
Complete Blood Counts (CBC):
Monitoring of blood cell parameters, especially lymphocyte and red cell counts is recommended to evaluate the subject’s progress. CBCs may be done every 2-4 weeks for patients that have lymphopenia and/or anemia.
T-Cyte recommends the following general treatment schedule:
For Treatment of FeLV, FIV, and LTCI 
